Welcome to the Stocktwits Top 25 Newsletter for Week 11 of 2023!
The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time.
Here are the Stocktwits Top 25 Lists for Week 11:
P.S. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!
Standard and Poor's 500
ST Top 25 S&P 500
The S&P 500 Top 25 list (+4.02%) outperformed the S&P 500 index (+1.43%).
There were four major changes to the list this week.
Joining: Arista Networks (+11.47%), FedEx (+9.50%), Applied Materials (+7.18%), and Fortinet (+4.19%).
Leaving: United Airlines (-15.56%), Steel Dynamics (-13.67%), Booking Holdings (-1.60%), and WW Grainger (-2.12%).
Check out how the momentum meter has performed vs. the S&P 500 index this year:
NASDAQ 100
The Large-Cap Nasdaq 100
The Nasdaq 100 Top 25 list (+5.76%) underperformed the Nasdaq 100 index (+5.83%).
There were four major changes to the list this week.
Joining: Amazon(+9.06%), Synopsys (+4.87%), Microsoft (+12.41%), and ASML Holding (+5.40%).
Leaving: Microchip Technology(-1.05%), Lucid Group (-2.29%), Copart (+1.93%), and IDEXX Laboratories (+3.63%).
RUSSELL 2000
The Growth-Centric Russell 2000
The Russell 2000 Top 25 list (+25.21%) outperformed the Russell 2000 index (-2.64%).
There were ten major changes to the list this week.
Joining: Riot Platforms (+52.83%), Marathon Digital Holdings (+53.28%), Provention Bio (+258.06%), Tyra Biosciences (+26.57%), Ironnet Inc (+35.29%), Redfin Inc (+22.62%), MicroStrategy (+39.40%), Fastly (+15.25%), Berkshire Grey (+15.46%), and Home Point Capital (+34.21%).
Leaving: Boxed Inc (-76.74%), Manitowoc Company (-9.01%), Blue Bird Corp (-6.16%), Diebold Nixdorf (-65.07%), Skywater Technology (-16.45%), BridgeBio Pharma (-3.63%), Hyster-Yale Materials Handling (-7.04%), Universal Insurance Holdings (-5.02%), Ocular Therapeutix (+1.85%), and Indie Semiconductor (+2.48%).
🐶🐶🐶
ST Top 25 TOP DAWG OF THE WEEK 🐶
The Top 25 lists’ Top Dawg was Provention Bio, which rallied 258.06%. 📈
The small-cap clinical-stage biopharmaceutical company jumped on the news that Sanofi will buy the company in a $2.9 billion all-cash deal. Sanofi will use the acquisition to bolster its work on a U.S.-approved type 1 diabetes therapy and strengthen its drug pipeline following development setbacks. 💉
The two companies previously had a co-promotion agreement, but now the French drug maker will fully own the Tzield drug. The acquisition is expected to be completed in the second quarter of 2023. 🤝
$PRVB is up 126.96% YTD.
See Y’all Next Week 🤙
